44 Wealth Management LLC Raises Holdings in Bristol Myers Squibb Company $BMY

44 Wealth Management LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 16.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 66,562 shares of the biopharmaceutical company’s stock after acquiring an additional 9,257 shares during the quarter. Bristol Myers Squibb makes up 1.0% of 44 Wealth Management LLC’s investment portfolio, making the stock its 19th largest position. 44 Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $3,002,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC raised its position in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the period. United Bank lifted its stake in shares of Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares in the last quarter. Bailard Inc. lifted its stake in shares of Bristol Myers Squibb by 17.7% during the 2nd quarter. Bailard Inc. now owns 8,426 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 1,266 shares in the last quarter. Finally, ABN Amro Investment Solutions bought a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $1,149,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BMY. Leerink Partners boosted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Citigroup raised their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Piper Sandler reiterated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Finally, Barclays assumed coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price for the company. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $61.00.

Bristol Myers Squibb Stock Up 0.1%

Shares of NYSE:BMY opened at $59.02 on Friday. The firm has a fifty day moving average price of $58.24 and a two-hundred day moving average price of $51.43. The company has a market cap of $120.18 billion, a price-to-earnings ratio of 17.11, a PEG ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the previous year, the company posted $1.67 EPS. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.